14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00308048
Recruitment Status : Completed
First Posted : March 28, 2006
Last Update Posted : July 6, 2011
Information provided by:
Oslo University Hospital

Brief Summary:
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

Condition or disease Intervention/treatment Phase
Hepatitis C Virus Infection Drug: Pegylated Interferon alfa 2b and ribavirin Phase 3

Detailed Description:

Patients with HCV genotype 2 or 3 infection are currently recommended 6 months treatment with pegylated interferon alfa (2a or 2b) and ribavirin.Approximately 80% obtain sustained virological response (HCV RNA undetectable 6 months after treatment) to this approach. However, the treatment is associated with many and sometimes serious side effects. In addition, the treatment is costly also in econimical terms. Increasing the treatment duration beyond 6 months does not increase the response rate. Shorter treatment has only been assessed in small trials, but the results have been encouraging.

In this randomised, open label,multicenter phase 3 trial with acitive controls patients are treated with pegylated interferon alfa 2a (PegIntron (R), Schering Plough NJ)(1,5 mcg/kg)and ribavirin (Rebetol (R), Schering Plough, NJ) (800-1400mg based on weight)for 4 weeks. Those who are HCV RNA negative at week 4 (<50 IU; Cobas Amplicor Monitor Test, Roche Diagnostic) are defined as rapid virological responders and randomised to either an additional 10 or 20 weeks combination treatment. Patients who are HCV RNA positive are all treated for 20 more weeks. The endpoint is sustained virological response defined as undetectable HCV RNA 24 weeks after end of treatment.

Our hypothesis is that there is no important difference in the effect in the two groups.

This is a non-inferiority trial. The smallest difference considered to be clinically important is 10%. Thus to state "non-inferiority" the 95% confidence interval of the observed difference between the groups shall not overlap 10%. Both intention to treat and and per protocol analyses will be published. Conclusion will be conservative and based on the analysis who detect the biggest difference.

Study Type : Interventional  (Clinical Trial)
Enrollment : 435 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
Study Start Date : March 2004
Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Interferon

Primary Outcome Measures :
  1. Sustained virological response (SVR) =HCV RNA negativity (<20 IU/ml) six months after end of treatment.

Secondary Outcome Measures :
  1. Change in health related quality as measured by short from 36 (SF-36) from baseline to 6 months after end of treatment.
  2. Sick leave in patients treated for 14 or 24 weeks treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

HCV RNA positive Genotype 2 or 3 Treatment naive Raised ALT

Exclusion Criteria:

Active substance abuse Poorly controlled psychiatric disease Decompensated cirrhosis HBsAg positive Anti-HIV positive Suffering from other significant concurrent medical conditions including chronic liver diseases -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00308048

Ullevaal University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Ullevaal University Hospital
Principal Investigator: Olav Dalgard, MD PhD Ullevaal University Hospital, Oslo, Norway

Publications: Identifier: NCT00308048     History of Changes
Other Study ID Numbers: P03720
First Posted: March 28, 2006    Key Record Dates
Last Update Posted: July 6, 2011
Last Verified: March 2006

Keywords provided by Oslo University Hospital:
Pegylated interferon
Pegylated interferon alfa 2b
Hepatitis C
Genotype 2
Genotype 3
Rapid virological response
Short treatment
14 weeks treatment
health related quality of life
sick leave
Injecting drug use

Additional relevant MeSH terms:
Hepatitis C
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Flaviviridae Infections
RNA Virus Infections
Peginterferon alfa-2b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs